Synvisc-One for Younger, Active Patients With Osteoarthritis

Not Applicable

Completed

Conditions: Osteoarthritis

Interventions: Device: Synvisc-One (G-F 20)

Registration Number: NCT01625013

Lead Sponsor: Anthony Luke

Brief Summary: This study aims to study use of viscosupplementation as a treatment of pain for young individuals who are active. Typically viscosupplementation is considered an intervention for knee osteoarthritis often for older patients who are less active. Many young active patients can also develop knee osteoarthritis after trauma or surgery or for congenital reasons. Treatment of these patients commonly are steroid injections which have more biologically detrimental effects for cartilage compared to viscosupplementation Synvisc One injections which are a single injection will be used to determine effectiveness of reducing pain and maintaining an active healthy lifestyle for younger patients aged 30-50 years old.

Detailed Description: This study will be an open label longitudinal cohort study with natural history over 3 years. Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study. Subjects enrolled in the cohort will have baseline functional testing performed including a motion gait analysis, 12 minute walk test, and 3-day accelerometer data. Subjects will receive a single 6 mL intra-articular injection of hylan G-F 20 in the target knee at baseline. All ongoing treatments will be monitored at 6 month intervals over the 3 year duration of the study. Patients can receive any other conservative treatments (e.g., oral medications, physical or other therapy, acupuncture, etc., except other injection treatments) and current treatments will be documented during each patient encounter. An initial injection of hylan G-F 20 will be injected in the symptomatic knee using a standard supine lateral approach using a 20 gauge needle. A face to face follow up visit will be carried out 6 months after first injection with additional face to face meetings every 6 months thereafter unless the subject requires an additional injection of hylan G-F 20. Hylan G-F 20 treatments can be administered up to three times each year during the study duration. After each injection, follow up measures will be carried out using secure e-mail or phone contact at 6 weeks, 12 weeks, 18 weeks after each in-office evaluation or injection. Follow up will consist of WOMAC, Lysholm score, and Tegner score. Patients may return for retreatment of hylan G-F 20 if symptoms recur after at least 4 months following their previous injection and they meet the inclusion criteria with pain levels of WOMAC A1, C8, C9, C10 and/or C23 equaling 2 or more. Patients requiring three injections of hylan G-F 20 in 4 months or less will be allowed to exit the cohort after their six-month follow up following the third injection. Otherwise, patients will be followed until they reach the 3 year follow up, or drop out for other injection treatments or surgical treatment. Therefore, patients would potentially be able to receive up to 9 injections during the 3 year study.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 51

Inclusion Criteria

Male or female patients aged 30-50 years
History of symptomatic unilateral primary or secondary knee OA for more than 6 months
Signed written informed consent
Radiographic evidence of Kellgren-Lawrence Grade I or II OA of the target knee
Body Mass Index (BMI) < 30 kg/m2
Activity criteria (Tegner score > 3)
Continued target knee OA pain despite conservative treatment ≥ 3 months (e.g., weight reduction, physical therapy, analgesics)
Willing to withhold intake of NSAIDs (including COX-2 inhibitors) and analgesics, for a washout period of minimum 3 days up to 21 days prior to baseline visit (depending on medication)
Willing to discontinue prohibited treatments and medications throughout study period

Baseline inclusion criteria

Completed OA medication washout period
Target knee pain 4-8 (0-10 NRS) during most painful knee movement (Worst Knee Pain)
If female, must have had a negative urine pregnancy test and used a medically acceptable form of contraception for at least 1 month prior to baseline and agree to continued use of contraception for the duration of the study. Otherwise, females must be surgically sterile, or postmenopausal (as documented in medical history) for at least 1 year. The fetal safety profile for G-F 20 is unknown. Pregnancy will affect the individual's regular activity levels. Females who become pregnant during the study will be excluded from the study. Subjects who become pregnant will be followed up by telephone every 3 months to check for any adverse effects. They will also be recommended to follow routine obstetric visits. Males should be able to father children as it has no expected effects on activity levels.

Exclusion Criteria

Known allergy to hylan G-F 20 or any of its components, or to avian proteins, eggs, feathers, down, or poultry
Clinically apparent tense effusion or other acute inflammation of the target knee at baseline
History of target knee viscosupplementation treatment
History of major surgery for OA in target knee including arthroplasty or tibial osteotomy
Arthroscopic surgery or intraarticular steroid injection in target knee within six months of baseline visit
Significant (as judged by the Investigator) alignment deformity of target knee
Ipsilateral symptomatic OA of hip or ankle; contralateral symptomatic OA of hip, knee, or ankle

History of:

Septic OA of any joint
Inflammatory arthropathy such as RA, gout, pseudogout, lupus, crystalline inflammatory arthropathy
Active infection of lower extremity
Known significant acute and/or concurrent medical disease including, but not limited to current malignancy, history of transplant surgery, congestive heart failure, significant unstable cardiovascular disease, renal hepatic pulmonary, endocrine, metabolic, or GI condition
Any known contraindication to acetaminophen
Venous or lymphatic stasis in either leg
Peripheral vascular disease
Patient has been prescribed chronic opioid analgesics at time of baseline visit
Concurrent multi-system or multi-limb trauma
Patient plans to become pregnant during study period
Patient plans to move significantly out of area, have surgery, or initiate or cease other OA treatments
Knee pain improves during washout period
Workman's Comp patient

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Synvisc-One	Synvisc-One (G-F 20)	-

Primary Outcome Measures

Name	Time	Method
"Worst Knee Pain" Likert Scale (0-10) Reported on Survey	26 weeks after injection at baseline	Worst Knee Pain Scores were measured using a "Worst Knee Pain" Likert scale, the score ranges from 0-10, zero indicating no pain and 10 indicating the worst pain. Patient Acceptable Symptom State (PASS) is a "Worst Knee Pain" reported score of less than 4 to be "positive". Patient Acceptable Symptom State (PASS) is the highest level of symptom beyond which patients consider themselves well. Minimum Clinical Important Improvement (MCII) is improvement at any time in the 26 week time frame that "Worst Knee Pain" is reported at 2 points less than baseline.

Secondary Outcome Measures

Name	Time	Method
Patient Acceptable Symptom Score (The Effect of Repeated Treatments)	26 weeks post-injection Number 2, an average of 52 weeks	Though symptoms can be improved for periods up to 6 months, pain symptoms can recur. The effect of repeated treatments of hylan G-F 20 will be studied with the Patient Acceptable Symptom Score less than 4/10 for the reported Worst Knee Pain score on follow up surveys. Worst Knee Pain Scores were measured using a "Worst Knee Pain" Likert scale, the score ranges from 0-10, zero indicating no pain and 10 indicating the worst pain. Patient Acceptable Symptom State (PASS) is a "Worst Knee Pain" reported score of less than 4 to be "positive". Patient Acceptable Symptom State (PASS) is the highest level of symptom beyond which patients consider themselves well.
Minimal Clinical Important Improvement (The Effect of Repeated Injections)	up to 15 months (within 3 months from the second Synvisc One injection)	Though symptoms can be improved for periods up to 6 months, pain symptoms can recur. The effect of repeated treatments of hylan G-F 20 will be studied with the Minimal Clinical Important Improvement less than 2 points from baseline on a 10-point likert scale for the reported Worst Knee Pain score on any follow up survey within 3 months. Worst Knee Pain Scores were measured using a "Worst Knee Pain" Likert scale, the score ranges from 0-10, zero indicating no pain and 10 indicating the worst pain. Patients can reinject after 4 months.
Identify the Effects of Treatment on Activity Levels	26 weeks post-injection at baseline through 3 years post-injection	To identify the effects of treatment with hylan G-F 20 on activity levels (using objective activity measures utilizing accelerometer and Physical Activity Enjoyment Scale (PACES) and quality of life scores (WOMAC, SF-12) comparing baseline to treatment at 3 months.